SCHEMBL10132641

SCHEMBL10132641

COc1ccccc1CNC(=O)c1ccc2c(c1)[nH]c(=O)c1ccsc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
POLB P06746 1/20 0.59
KDM4E B2RXH2 1/20 0.56
PARP1 P09874 2/20 0.54
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
CSNK2A1 P68400 1/20 0.54
ATM Q13315 1/20 0.52
HDAC1 Q13547 1/20 0.51
HPGD P15428 2/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 1/20 0.51
PAX8 Q06710 1/20 0.51
HTT P42858 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
EPHX2 P34913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648695 0.86 PARP1 (0.58) MAPTPOLBKDM4EPARP1CSNK2A2
SCHEMBL10132603 0.83 MEN1 (0.57) POLBPARP1CSNK2A2CSNK2BCSNK2A1
SCHEMBL10132633 0.83 PARP1 (0.65) MAPTKDM4EPARP1CSNK2A2CSNK2B
SCHEMBL10132584 0.82 MAPT (0.58) MAPTPOLBKDM4EPARP1CSNK2A2
SCHEMBL10132586 0.81 PARP1 (0.61) MAPTKDM4EPARP1CSNK2A2CSNK2B
SCHEMBL10132625 0.81 PARP1 (0.61) MAPTKDM4EPARP1CSNK2A2CSNK2B
SCHEMBL10132626 0.79 ALDH1A1 (0.63) MAPTPOLBKDM4EPARP1CSNK2A2
SCHEMBL10132645 0.79 KDM4E (0.57) POLBKDM4EPARP1CSNK2A2CSNK2B
SCHEMBL10132620 0.78 PARP1 (0.64) MAPTPOLBKDM4EPARP1CSNK2A2
SCHEMBL13648692 0.78 ALDH1A1 (0.54) MAPTPOLBKDM4EPARP1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-7956064-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS, INC. (US) 2011-06-07 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PARP1, PARP11, TNKS MAPT 1389/4885POLB 747/4885KDM4E 1489/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 MAPT 3042/4885POLB 894/4885KDM4E 736/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 MAPT 1369/4885POLB 709/4885KDM4E 1151/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 MAPT 3042/4885POLB 894/4885KDM4E 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.